Loading
A phase 3 trial of Nivolumab, Carboplatin, Cisplatin, Pemetrexed and Docetaxel in non-small-cell lung cancer, run by Bristol-Myers Squibb, active and no longer recruiting.
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer is a phase 3 interventional study registered as NCT04025879 by Bristol-Myers Squibb, with 461 participants enrolled, started 2019-11-05 and due to reach its primary completion in 2023-07-26. Interventions recorded: Nivolumab, Carboplatin, Cisplatin, Paclitaxel, Pemetrexed and Placebo. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
461 enrolled.
Insufficient number of participants with events; Figures from the ClinicalTrials.gov results section (first posted 2024-07-23), not from a publication · 95% CI 13.63 to 28.06
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Event-Free Survival (EFS) by BICRprimary | Nivolumab + SOC Chemotherapy | 229 | Insufficient number of participants with events; Figures from the ClinicalTrials.gov results section (first posted 2024-07-23), not from a publication | - | 0.00025 | link |
| Placebo + SOC Chemotherapy | 232 | 18.43 months |
Shares Pemetrexed, Bristol Myers Squibb, Cisplatin, Carboplatin and the tag pipeline.
Shares Resectable stage I to III non-small-cell lung cancer, Pemetrexed, Cisplatin, Carboplatin and the tag pipeline.
Shares Pemetrexed, Bristol Myers Squibb, Cisplatin, Carboplatin and the tag pipeline.
Shares Pemetrexed, Nivolumab, Cisplatin, Carboplatin and the tag pipeline.
Shares Bristol Myers Squibb, Nivolumab, Cisplatin, Carboplatin and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Immune checkpoint inhibitors and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Immune checkpoint inhibitors and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Immune checkpoint inhibitors and the tag pipeline.